Oklahoma Blood Institute

Oklahoma Blood Institute, a non-profit blood bank based in Oklahoma City, supplies human blood, blood products, immunohematology testing, and transfusion services to the Department of Veterans Affairs and the Indian Health Service as a prime contractor on sole-source and competitive blanket purchase agreements and indefinite-delivery contracts, with no subcontracting footprint and no set-aside designations.

Oklahoma Blood Institute operates exclusively as a prime contractor (100% of recent awards) across federal healthcare supply. The organization has maintained federal vendor registration since October 2001 and competes full-and-open across all award vehicles. Recent awards span blood product procurement, component preparation, compatibility screening, specialized plasma processing, and immunohematology reference laboratory services. Representative work includes a $7.788 billion blanket purchase agreement ceiling with Veterans Integrated Service Network 19 running through September 2028 (with a $1.366 million call awarded October 2024 and a $1.29 million call awarded October 2025 for blood products to Oklahoma City and Tulsa VA medical centers), a $5.088 million indefinite-delivery contract with VISN 16 through November 2027 (four delivery orders totaling approximately $2.819 million for blood and transfusion testing services in Oklahoma City), and a $325,000 blanket purchase agreement with the Indian Health Service established September 2026 for blood products and immunohematology reference laboratory services at the Lawton Indian Hospital.

Customer concentration is heavily weighted to a single major customer. The top five funding agencies account for 62% of awards by count, but the dollar concentration is more acute: Veterans Integrated Service Network 19 anchors 64% of combined potential value ($65.4 million across 42 awards), and VISN 16 adds another $16.9 million (16% of portfolio dollars). Together, the two VA networks represent roughly 80% of the portfolio's combined potential value of $102.7 million. The Indian Health Service (72 awards, $5.4 million combined potential value) and the Army Medical Command (55 awards, $6.4 million) round out the customer base but carry much smaller dollar exposure. This concentration reflects Oklahoma Blood Institute's strategic positioning as the sole-source blood supplier to two large VA networks serving Oklahoma, Texas, Arkansas, and surrounding states.

Award activity has declined in recent years. Oklahoma Blood Institute received nine awards in 2022, twelve in 2023, seven in 2024, six in 2025, and four through September 2026. The combined potential value across all 437 awards in the source data is $102.7 million, with $47.3 million obligated to date (46% utilization). Seven awards with combined potential value of $3.5 million face ultimate completion within the next twenty-four months, presenting recompete exposure primarily in VISN 19 and VISN 16 renewal cycles. The primary IDVs driving volume are an Indefinite Delivery Contract (V580P7542) with 59 task orders and an Indefinite Delivery Contract (V580P7840) with 57 task orders, both generating modest combined potential values ($1.5 million and $403 thousand respectively), suggesting high-volume, low-dollar-per-order patterns typical of recurring blood supply procurement.

Portfolio composition is tightly aligned to blood banking. The top NAICS is 422210 (Blood and Organ Banks), accounting for 337 of 437 awards. Secondary categories — Biological Product Manufacturing (14 awards), Medical Laboratories (10 awards) — reflect immunohematology and testing scope. PSC distribution shows Drugs and Biologicals (174 awards), Medical and Surgical Instruments and Supplies (46 awards), and Reference Laboratory Testing (36 awards), confirming narrow focus on transfusion services and blood component supply with minimal diversification into other medical product categories.